Sovereign patent lapses dismantle the global weight-loss monopoly ahead of schedule.
While brand-name drugmakers tightly defend their core Western patents, localized expirations in foreign jurisdictions fuel a rapid, low-cost wave of generic copycats that erodes pricing integrity.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
European patent revocations are pulling the generic semaglutide date forward years ahead of the Western patent wall, dismantling the monopoly ahead of schedule.
The expiration of brand patents in secondary national jurisdictions unleashes an immediate wave of regional generic copycats that erodes pricing power.
A foreign patent lapse lets a low-cost copycat undercut branded pricing ahead of Western expiries.